BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Regeneron Pharmaceuticals, Inc. (REGN) Announces January 2013 Investor Conference Presentations


12/20/2012 8:08:04 AM

TARRYTOWN, N.Y., Dec. 20, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the following investor conferences:

  • Goldman Sachs Healthcare CEOs Unscripted:  A View from the Top on Thursday, January 3, 2013.  The session is scheduled for 3:15 p.m. Eastern Time.
  • 31st Annual J. P. Morgan Healthcare Conference on Tuesday, January 8, 2013.  The presentation is scheduled for 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

The sessions may be accessed through the Company's web site, www.regeneron.com, on the 'Events and Presentations' page.  An archived version of the presentation will be available for 30 days.

Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets three products in the United States, EYLEA® (aflibercept) Injection, ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST® (rilonacept) Injection for Subcutaneous Use; ZALTRAP is co-commercialized with Sanofi.  Phase 3 studies are in progress with EYLEA in two additional indications and with product candidates sarilumab and REGN727.  Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia.  Additional information and recent news releases are available on the Regeneron web site at www.regeneron.com.

Contact Information:




Michael Aberman, M.D.                       

Peter Dworkin

Investor Relations                                

Corporate Communications                           

914.847.7799                                           

914.847.7640             

michael.aberman@regeneron.com             

peter.dworkin@regeneron.com

 

SOURCE Regeneron Pharmaceuticals, Inc.


Read at BioSpace.com

Related News

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->